相关实验视频
Updated: Jun 23, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.8K
关于与杜洛特格拉维尔相关的体重增加和二次代谢并发症的审查
1Department of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Amhara, Ethiopia.
SAGE open medicine
|June 17, 2024
概括
多卢特格拉维尔是一种首选的人类免疫缺陷病毒 (HIV) 治疗方法,与显著的体重增加有关. 本综述探讨了这种新兴问题的代谢后果和潜在机制.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 多卢特格拉维尔是世卫组织推用于艾滋病毒治疗的整合酶抑制剂.
- 体重增加是基于dolutegravir的疗法的一个新兴问题.
- 这种体重增加的长期代谢影响尚未完全理解.
研究的目的:
- 审查当前对与多卢特格拉维尔相关的体重增加和脂肪变化的理解.
- 为了探索潜在的二次代谢并发症.
- 讨论杜洛特格拉维尔诱导的体重增加背后可能的机制.
主要方法:
- 关于多卢特格拉维尔,体重增加和代谢变化研究的文献综述.
- 分析证据,将杜洛特格拉维尔与高血糖症,高血压和代谢综合征联系起来.
- 检查涉及食欲调节和脂肪组织的拟议机制.
主要成果:
- 基于多卢特格拉维尔的疗法与过度体重增加有关.
- 这种体重增加与高血糖,高血压和心血管风险的增加有关.
- 有证据表明脂肪细胞分化和脂质储存标记的增加.
结论:
- 与多卢特格拉维尔相关的体重增加带来了重大的代谢挑战.
- 需要进一步的研究来阐明精确的机制.
- 了解这些机制对于管理服用多卢特格拉维尔的艾滋病毒患者至关重要.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Gastroesophageal Reflux Disease II: Clinical Features and Management
68
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
68
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Sulfonylureas
200
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
200

